Neurotoxicity Research

, Volume 25, Issue 4, pp 335–347 | Cite as

Role of Nuclear Receptor on Regulation of BDNF and Neuroinflammation in Hippocampus of β-Amyloid Animal Model of Alzheimer’s Disease

  • Atish PrakashEmail author
  • Anil Kumar
Original Article


Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have been reported to provide neuroprotective effects against neurodegenerative diseases. The current study was carried out to investigate the effects of chronic administration of pioglitazone, a PPAR-γ agonist, on cognitive impairment in an animal model of Alzheimer’s disease induced by β-amyloid. Wistar rats received intracerebroventricular (ICV) β-amyloid (βA) application (3 nmol/3 μL), and behavioral alterations (locomotor activity and memory performance) were assessed. Animals were sacrificed immediately following the last behavioral session, and their brains were removed and dissected. Mitochondrial enzymes, oxidative parameters, inflammatory mediators (TNF-α, IL-6), caspase activity, and BDNF levels were measured in the hippocampus. ICV βA-treated rats showed a memory deficit and significantly decreased BDNF level, simultaneously, increase in mitochondrial oxidative damage and inflammatory mediators in the hippocampus. Memory impairment and oxidative damage were reversed by administration of pioglitazone (15 and 30 mg/kg). Pioglitazone also significantly restored the BDNF level and attenuated the actions of inflammatory markers in ICV βA-treated rats. However, pretreatment with PPAR-γ antagonist BADGE (15 mg/kg) with higher dose of pioglitazone significantly reversed its protective action in memory impairment in βA-treated rats, which indicates the involvement of PPAR-γ receptors mediating neuroprotective action. These results demonstrate that pioglitazone offers protection against β-amyloid-induced memory dysfunction possibly due to its antioxidant, anti-inflammatory, anti-apoptotic action and neurogenesis-like effect therefore, could have a therapeutic potential in Alzheimer’s disease.


Amyloid BDNF PPAR-γ Apoptosis Mitochondria 



Authors are thankful to the financial support of Indian Council of Medical Research (ICMR), New Delhi for carrying out this work.


  1. Allami N, Javadi-Paydar M, Rayatnia F, Sehhat K, Rahimian R, Norouzi A, Dehpour AR (2011) Suppression of nitric oxide synthesis by L-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Eur J Pharmacol 650:240–248PubMedCrossRefGoogle Scholar
  2. Aoun P, Simpkins JW, Agarwal N (2003) Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Invest Ophthalmol Vis Sci 44(7):2999–3004PubMedCrossRefGoogle Scholar
  3. Arshavsky YI (2010) Why Alzheimer’s disease starts with memory impairment: neurophysiological insight. J Alzheimers Dis 20:5–16PubMedGoogle Scholar
  4. Bishop-Bailey D (2009) Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation. Bystrom J Pharmacol Ther 124:141–150CrossRefGoogle Scholar
  5. Brandolic Sanic A, De Bemardi MA (1998) BDNF and bFGF down regulate NMDA receptor function in cerebella anole cells. Neuroscience 18:7153–7161Google Scholar
  6. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B (2004) Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 24:10908–10917PubMedCrossRefGoogle Scholar
  7. Celsi F, Pizzo P, Brini M, Leo S, Fotino C, Pinton P, Rizzuto R (2009) Mitochondria, calcium and cell death: a deadly triad in neurodegeneration. Biochim Biophys Acta 1787:335–344PubMedCentralPubMedCrossRefGoogle Scholar
  8. Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M (1997) Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Brain Res Mol Brain Res 49(1–2):71–81PubMedCrossRefGoogle Scholar
  9. d’Abramo C, Massone S, Zingg JM, Pizzuti A, Marambaud P, Dalla Piccola B, Azzi A, Marinari UM, Pronzato MA, Ricciarelli R (2005) Role of peroxisome proliferator-activated receptor-gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J 391:693–698PubMedCentralPubMedCrossRefGoogle Scholar
  10. Daynes RA, ones DC (2002) Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2:748–759PubMedCrossRefGoogle Scholar
  11. Diógenes MJ, Costenla AR, Lopes LV, Jerónimo-Santos A, Sousa VC, Fontinha BM, Ribeiro JA, Sebastião AM (2011) Enhancement of LTP in aged rats is dependent on endogenous BDNF. Neuropsychopharmacology 36:1823–1836PubMedCentralPubMedCrossRefGoogle Scholar
  12. Duff K, Paulsen J, Mills J, Beglinger LJ, Moser DJ, Smith MM, Langbehn D, Stout J, Queller S, Harrington DL (2010) Mild cognitive impairment in prediagnosed Huntington disease. Neurology 75(6):500–507PubMedCentralPubMedCrossRefGoogle Scholar
  13. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77PubMedCrossRefGoogle Scholar
  14. Ellman GL, Courtney V, Andres RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95PubMedCrossRefGoogle Scholar
  15. Ferrer Krupinski J, Goutan E (2001) Brain-derived neurotrophic factor reduces cortical cell death by ischemia after middle cerebral artery occlusion in the rat. Acta Neuropathol 101:229–238PubMedGoogle Scholar
  16. Fukui K, Takatsu H, Suzuki S, Abe K, Urano S (2005) Appearance of amyloid-like substances and delayed-type apoptosis in rat hippocampus CA1 region through aging and oxidative stress. J Alzheimer’s Dis 8(3):299–309Google Scholar
  17. Gornall AG, Bardawill CT, David MM (1949) Determination of serum proteins by means of Biuret reaction. J Biol Chem 177:751–766PubMedGoogle Scholar
  18. Green LC, Wagner DA, Glagowski J (1982) Analysis of nitrate, nitrite and (15N) nitrate in biological fluids. J Biol Chem 193:265–275Google Scholar
  19. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O’Banion K, Klockgether T, Van Leuven F, Landreth GE (2005) Acute treatment with the PPAR gamma agonist pioglitazone and ibuprofen reduces glial inflammation and A{beta}1-42 levels in APPV717I transgenic mice. Brain 128:1442–1453PubMedCrossRefGoogle Scholar
  20. Heneka MT, Reyes-Irisarri E, Hüll M, Kummer MP (2011) Impact and therapeutic potential of PPARs in Alzheimer’s disease. Curr Neuropharmacol 9:643–650PubMedCentralPubMedCrossRefGoogle Scholar
  21. Kaur B, Singh N, Jaggi AS (2009) Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia. Fundam Clin Pharmacol 23:557–566PubMedCrossRefGoogle Scholar
  22. King TE (1967) Preparation of succinate dehydrogenase and reconstitution of succinate oxidase. Methods Enzymol 10:322–331CrossRefGoogle Scholar
  23. King TE, Howard RL (1967) Preparations and properties of soluble NADH dehydrogenases from cardiac muscle. Methods Enzymol 10:275–284CrossRefGoogle Scholar
  24. Kono Y (1978) Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 186:189–195PubMedCrossRefGoogle Scholar
  25. Kumar A, Prakash A, Dogra S (2010) Naringin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress induced by d-galactose in mice. Food Chem Toxicol 48:626–632PubMedCrossRefGoogle Scholar
  26. Landreth G, Jiang Q, Mandrekar S, Heneka M (2008) PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics 5(3):481–489PubMedCentralPubMedCrossRefGoogle Scholar
  27. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457:U1128–U1184CrossRefGoogle Scholar
  28. Lee S, Fernandez EJ, Good TA (2007) Role of aggregation conditions in structure, stability, and toxicity of intermediates in the A beta fibril formation pathway. Protein Sci 16:723–732PubMedCentralPubMedCrossRefGoogle Scholar
  29. Liu Y, Peterson DA, Kimura H, Schubert D (1997) Mechanisms of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolinium bromide (MTT) reduction. J Neurochem 69:581–593PubMedCrossRefGoogle Scholar
  30. Luck H (1971) Catalase. In: Bergmeyer HJ (ed) Methods of Enzymatic analysis, 3rd edn. Academic Press, New York, pp 885–893 vol. IIIGoogle Scholar
  31. Mark RJ, Hensley K, Butterfield DA, Mattson MP (1995) Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death. J Neurosci 15:6239–6249PubMedGoogle Scholar
  32. Maurice T, Lockhart BP, Privat A (1996) Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706:181–193PubMedCrossRefGoogle Scholar
  33. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R (2009) PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int 55:496–504PubMedCrossRefGoogle Scholar
  34. Nicolakakis N, Hamel E (2010) The nuclear receptor PPARgamma as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer’s disease. Front Aging Neurosci 2:21PubMedCentralPubMedCrossRefGoogle Scholar
  35. Pike KE, Ellis KA, Villemagne VL, Good N, Chetelat G, Ames D, Szoeke C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC (2011) Cognition and beta-amyloid in preclinical Alzheimer’s disease: data from the AIBL study. Neuropsychologia 49:2384–2390PubMedCrossRefGoogle Scholar
  36. Prakash A, Kumar A (2009) Effect of N-acetyl cysteine against aluminium-induced cognitive dysfunction and oxidative damage in rats. Basic Clin Pharmacol Toxicol 105:98–104PubMedCrossRefGoogle Scholar
  37. Prakash A, Kumar A (2013) Pioglitazone alleviates the mitochondrial apoptotic pathway and mito-oxidative damage in the d-galactose-induced mouse model. Clin Exp Pharmacol Physiol 40(9):644–651PubMedCrossRefGoogle Scholar
  38. Reddy PH, McWeeney S (2006) Mapping cellular transcriptosomes in autopsied Alzheimer’s disease subjects and relevant mouse models. Neurobiol Aging 27(8):1060–1077PubMedCrossRefGoogle Scholar
  39. Rial D, Piermartiri TC, Duarte FS, Tasca CI, Walz R, Prediger RD (2012) Overexpression of cellular prion protein (PrP(C)) prevents cognitive dysfunction and apoptotic neuronal cell death induced by amyloid-β (Aβ(1-40)) administration in mice. Neuroscience 215:79–89PubMedCrossRefGoogle Scholar
  40. Rozemuller AJ, Jansen C, Carrano A, van Haastert ES, Hondius D, van der Vies SM, Hoozemans JJ (2012) Neuroinflammation and common mechanism in Alzheimer’s disease and prion amyloidosis: amyloid-associated proteins, neuroinflammation and neurofibrillary degeneration. Neurodegener Dis 10:301–304PubMedCrossRefGoogle Scholar
  41. Ruan CJ, Zhang L, Chen DH, Li Z, Du GH, Sun L (2010) Effects of trans-2,4-dimethoxystibene against the neurotoxicity induced by Abeta(25–35) both in vitro and in vivo. Neurosci Res 67(3):209–214PubMedCrossRefGoogle Scholar
  42. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23:9796–9804PubMedGoogle Scholar
  43. Saxena G, Patro IK, Nath C (2011) ICV STZ induced impairment in memory and neuronal mitochondrial function: a protective role of nicotinic receptor. Behav Brain Res 224:50–57PubMedCrossRefGoogle Scholar
  44. Siemers E (2011) Designing clinical trials for early (pre-dementia) Alzheimer’s disease: determining the appropriate population for treatment. J Nutr Health Aging 15(1):22–24PubMedCrossRefGoogle Scholar
  45. Smith MA, Makino S, Kim SY, Kvetnansky R (1995) Stress increases brain-derived neurotropic factor messenger ribonucleic acid in the hypothalamus and pituitary. Endocrinology 136:3743–3750PubMedGoogle Scholar
  46. Sottocasa GL, Kuylenstierna B, Ernster L, Bergstrand A (1967) An electron-transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J Cell Biol 32:415–438PubMedCentralPubMedCrossRefGoogle Scholar
  47. Spuch C, Ortolano S, Navarro C (2012) New insights in the amyloid–beta interaction with mitochondria. J Aging Res 324968. doi: 10.1155/2012/324968
  48. Stéphan A, Phillips AG (2005) A case for a non-transgenic animal model of Alzheimer’s disease. Genes Brain Behav 4(3):157–172PubMedCrossRefGoogle Scholar
  49. Storer PD, Xu J, Chavis J, Drew PD (2005) Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol 161:113–122PubMedCrossRefGoogle Scholar
  50. Sun H, Zhang J, Zhang L, Liu H, Zhu H, Yang Y (2010) Environmental enrichment influences BDNF and NR1 levels in the hippocampus and restores cognitive impairment in chronic cerebral hypoperfused rats. Curr Neurovasc Res 7:268–280PubMedCrossRefGoogle Scholar
  51. Sundararajan S, Jiang Q, Heneka M, Landreth G (2006) PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int 49(2):136–144PubMedCrossRefGoogle Scholar
  52. Tam JH, Pasternak SH (2012) Amyloid and Alzheimer’s disease: inside and out. Can J Neurol Sci 39:286–298PubMedGoogle Scholar
  53. Tanzi R, Bertram L (2005) Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 120:545–555PubMedCrossRefGoogle Scholar
  54. Tillement L, Lecanu L, Papadopoulos V (2011) Alzheimer’s disease: effects of β-amyloid on mitochondria. Mitochondrion 1:13–21CrossRefGoogle Scholar
  55. Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL, Mori H (2011) Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res 89:1031–1042PubMedCrossRefGoogle Scholar
  56. Wills ED (1966) Mechanism of lipid peroxide formation in animal tissues. Biochemical J 99:667–676Google Scholar
  57. Zhang HY, Liu YH, Wang HQ, Xu JH, Hu HT (2008) Puerarin protects PC12 cells against beta-amyloid-induced cell injury. Cell Biol Int 32:1230–1237PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Pharmacology DivisionUniversity Institute of Pharmaceutical Sciences, Panjab UniversityChandigarhIndia
  2. 2.Pharmacology DivisionIndo Soviet College of PharmacyMogaIndia

Personalised recommendations